Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
作者信息
Charbonneau C, Sandin R
出版信息
Br J Cancer. 2010 Oct 12;103(8):1307-8; author reply 1309-10. doi: 10.1038/sj.bjc.6605886. Epub 2010 Sep 14.
Abstract
摘要
相似文献
1
Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.对“一线转移性肾细胞癌治疗中不良事件管理的成本：贝伐单抗联合干扰素-α2a与舒尼替尼的比较”的评论
Br J Cancer. 2010 Oct 12;103(8):1307-8; author reply 1309-10. doi: 10.1038/sj.bjc.6605886. Epub 2010 Sep 14.
2
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.关于：“一线转移性肾细胞癌治疗中不良事件管理的成本：贝伐单抗联合α-干扰素2a与舒尼替尼的比较”
Br J Cancer. 2010 Mar 30;102(7):1196-7. doi: 10.1038/sj.bjc.6605585. Epub 2010 Feb 23.
3
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.一线转移性肾细胞癌治疗中不良反应管理成本：贝伐珠单抗联合干扰素-α2a 与舒尼替尼比较。
Br J Cancer. 2010 Jan 5;102(1):80-6. doi: 10.1038/sj.bjc.6605417. Epub 2009 Nov 17.
4
Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.贝伐珠单抗联合干扰素-α对比舒尼替尼用于意大利肾细胞癌一线治疗的成本最小化分析。
Clin Drug Investig. 2011;31(7):507-17. doi: 10.2165/11590230-000000000-00000.
5
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.舒尼替尼和贝伐单抗用于转移性肾细胞癌一线治疗：临床疗效的系统评价和间接比较
Br J Cancer. 2009 Jul 21;101(2):238-43. doi: 10.1038/sj.bjc.6605167. Epub 2009 Jun 30.
6
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.贝伐珠单抗、索拉非尼甲苯磺酸盐、舒尼替尼和替西罗莫司治疗肾细胞癌：系统评价和经济评估。
Health Technol Assess. 2010 Jan;14(2):1-184, iii-iv. doi: 10.3310/hta14020.
7
Tolerability of first-line therapy for metastatic renal cell carcinoma.转移性肾细胞癌一线治疗的耐受性
Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26.
8
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.舒尼替尼联合贝伐单抗治疗肾细胞癌的毒性反应
J Clin Oncol. 2010 Jun 10;28(17):e284-5; author reply e286-7. doi: 10.1200/JCO.2009.27.1759. Epub 2010 May 3.
9
Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.二线贝伐珠单抗联合干扰素-α治疗舒尼替尼耐药转移性肾细胞癌的疗效良好。
Anticancer Drugs. 2010 Feb;21(2):210-3. doi: 10.1097/CAD.0b013e3283340d1f.
10
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.转移性肾细胞癌的靶向治疗：毒性及给药策略概述
Oncologist. 2008 Oct;13(10):1084-96. doi: 10.1634/theoncologist.2008-0120. Epub 2008 Oct 6.
引用本文的文献
1
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.舒尼替尼作为多靶点酪氨酸激酶抑制剂（TKI）在实体癌中的临床反应：临床试验综述
Onco Targets Ther. 2014 May 12;7:719-28. doi: 10.2147/OTT.S61388. eCollection 2014.
本文引用的文献
1
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.关于：“一线转移性肾细胞癌治疗中不良事件管理的成本：贝伐单抗联合α-干扰素2a与舒尼替尼的比较”
Br J Cancer. 2010 Mar 30;102(7):1196-7. doi: 10.1038/sj.bjc.6605585. Epub 2010 Feb 23.
2
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.贝伐珠单抗、索拉非尼甲苯磺酸盐、舒尼替尼和替西罗莫司治疗肾细胞癌：系统评价和经济评估。
Health Technol Assess. 2010 Jan;14(2):1-184, iii-iv. doi: 10.3310/hta14020.
3
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.一线转移性肾细胞癌治疗中不良反应管理成本：贝伐珠单抗联合干扰素-α2a 与舒尼替尼比较。
Br J Cancer. 2010 Jan 5;102(1):80-6. doi: 10.1038/sj.bjc.6605417. Epub 2009 Nov 17.
4
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.舒尼替尼用于转移性肾细胞癌的安全性和有效性：一项扩大准入试验。
Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15.
5
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.舒尼替尼和贝伐单抗用于转移性肾细胞癌一线治疗：临床疗效的系统评价和间接比较
Br J Cancer. 2009 Jul 21;101(2):238-43. doi: 10.1038/sj.bjc.6605167. Epub 2009 Jun 30.
6
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌患者的总生存期及更新结果比较
J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.
7
Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.转移性肾细胞癌的治疗：一项间接比较的荟萃分析。
BMC Cancer. 2009 Jan 27;9:34. doi: 10.1186/1471-2407-9-34.
8
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.舒尼替尼或干扰素α治疗转移性肾细胞癌患者的生活质量：一项III期随机试验的结果
J Clin Oncol. 2008 Aug 1;26(22):3763-9. doi: 10.1200/JCO.2007.13.5145.
Zotero 插件